Stocktoria
TuHURA Biosciences, Inc./NV HURA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-07-12
TuHURA Biosciences, Inc./NV financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | — | — | — | — | — | — |
| R&D expense | $20.5M | $13.3M | $2.7M | $9.4M | $9.3M | $15.2M | $11.8M | $3.6M | $3.7M | -$7.1M |
| Interest expense | $625,283 | $4.1M | — | $18,688 | — | — | $30,000 | — | — | — |
| Income tax | $1,600 | $3,768 | — | $0 | — | — | — | — | — | — |
| Net income | -$30.1M | -$21.7M | -$8.3M | -$29.3M | -$14.6M | -$22.7M | -$38.3M | -$9.1M | -$8.0M | $11.1M |
| EPS (diluted) | $-0.63 | $-1.21 | — | $-2.47 | — | — | — | — | — | — |
| Operating cash flow | -$27.6M | -$14.7M | -$7.2M | -$12.0M | -$11.9M | -$20.4M | -$18.9M | -$7.9M | -$6.3M | -$9.9M |
| Free cash flow | -$27.7M | -$14.8M | — | -$12.0M | — | -$20.6M | — | — | — | — |
| Cash & equivalents | $3.6M | $12.7M | $4.9M | $3.7M | $1.5M | $11.8M | $10.5M | $2.4M | $3.7M | $6.0M |
| Total assets | $27.4M | $20.0M | $6.2M | $4.4M | $4.0M | $15.9M | $13.5M | $2.9M | $4.0M | $7.1M |
| Total liabilities | $6.4M | $5.4M | $2.4M | $5.9M | $3.2M | $4.2M | $3.0M | $2.7M | $2.1M | $1.6M |
| Shareholders' equity | $20.9M | $14.6M | -$7.0M | -$1.6M | $731,000 | $11.8M | $10.6M | $263,000 | $2.0M | $5.4M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth | — | — | — | — | — | — | — | — | -172.3% | +37.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.